moxifloxacin has been researched along with tazobactam in 5 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (tazobactam) | Trials (tazobactam) | Recent Studies (post-2010) (tazobactam) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 1,327 | 153 | 694 |
| Protein | Taxonomy | moxifloxacin (IC50) | tazobactam (IC50) |
|---|---|---|---|
| Beta-lactamase | Klebsiella pneumoniae | 0.08 | |
| Beta-lactamase | Escherichia coli | 0.01 | |
| Beta-lactamase | Citrobacter freundii | 0.096 | |
| Beta-lactamase | Citrobacter gillenii | 0.04 | |
| Beta-lactamase | Shouchella clausii | 0.004 | |
| Beta-lactamase | Burkholderia cenocepacia | 0.5 | |
| Beta-lactamase | Pseudomonas aeruginosa | 0.06 | |
| Beta-lactamase | Pseudomonas aeruginosa | 2 | |
| B2 bradykinin receptor | Cavia porcellus (domestic guinea pig) | 4.8 | |
| Beta-lactamase | Staphylococcus aureus | 0.5 | |
| Beta-lactamase | Bacillus licheniformis | 0.51 | |
| Beta-lactamase | Escherichia coli K-12 | 0.25 | |
| Beta-lactamase | Citrobacter freundii | 0.93 | |
| Beta-lactamase | Enterobacter cloacae | 1.3748 | |
| Beta-lactamase SHV-1 | Escherichia coli | 0.222 | |
| Beta-lactamase SHV-1 | Klebsiella pneumoniae | 0.11 | |
| Beta-lactamase OXA-1 | Escherichia coli | 4.8 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.83 | |
| Cytochrome P450 2B6 | Homo sapiens (human) | 0.11 | |
| Beta-lactamase | Pseudomonas aeruginosa PAO1 | 2.51 | |
| Beta-lactamase TEM | Escherichia coli | 0.0828 | |
| Beta-lactamase | Morganella morganii | 0.19 | |
| Beta-lactamase | Salmonella enterica subsp. enterica serovar Westhampton | 0.0022 | |
| Beta-lactamase | Pseudomonas aeruginosa | 2 | |
| Beta-lactamase | Enterobacter cloacae | 0.03 | |
| Class D beta-lactamase | Brachyspira pilosicoli | 0.16 | |
| Beta-lactamase | Pseudomonas luteola | 0.04 | |
| Beta-lactamase | Escherichia coli | 0.24 | |
| Beta-lactamase | Serratia fonticola | 6.9 | |
| Beta-lactamase | Enterobacter cloacae | 0.06 | |
| Beta-lactamase | Escherichia coli | 0.002 | |
| Carbapenem-hydrolyzing beta-lactamase KPC | Klebsiella pneumoniae | 0.372 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, SH; Franzblau, SG; Hwang, CH; Pauli, GF; Wan, B; Warit, S | 1 |
| Choi, MK; Fish, DN; Husain, M; Jung, R | 1 |
| Choudhri, S; Giordano, P; Lipsky, BA; Song, J | 1 |
| Alder, J; Arvis, P; Dryden, M; Gyssens, IC; Kujath, P; Nathwani, D; Reimnitz, P; Schaper, NC | 1 |
| Li, J; Li, N; Liu, B; Lü, X; Wang, H; Zhang, Y | 1 |
2 trial(s) available for moxifloxacin and tazobactam
| Article | Year |
|---|---|
Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate.
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Bacterial Infections; Databases, Factual; Diabetic Foot; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Penicillanic Acid; Piperacillin; Quinolines; Tazobactam | 2007 |
Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study.
Topics: Administration, Intravenous; Administration, Oral; Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Bacteria; Bacterial Infections; Diabetic Foot; Female; Fluoroquinolones; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Penicillanic Acid; Piperacillin; Quinolines; Tazobactam; Treatment Outcome | 2013 |
3 other study(ies) available for moxifloxacin and tazobactam
| Article | Year |
|---|---|
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
Topics: Anti-Bacterial Agents; Antitubercular Agents; DNA, Bacterial; Drug Evaluation, Preclinical; Mycobacterium tuberculosis; Oxygen | 2007 |
Synergistic activities of moxifloxacin combined with piperacillin-tazobactam or cefepime against Klebsiella pneumoniae, Enterobacter cloacae, and Acinetobacter baumannii clinical isolates.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Infective Agents; Aza Compounds; Cefepime; Cephalosporins; Colony Count, Microbial; Drug Synergism; Enterobacter cloacae; Enterobacteriaceae Infections; Enzyme Inhibitors; Fluoroquinolones; Humans; Klebsiella Infections; Klebsiella pneumoniae; Moxifloxacin; Penicillanic Acid; Penicillins; Piperacillin; Quinolines; Tazobactam | 2004 |
Antibiotic susceptibility and biofilm-forming ability of Veillonella strains.
Topics: Ampicillin; Anti-Bacterial Agents; Biofilms; Cefoxitin; Clindamycin; Humans; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Piperacillin; Tazobactam; Tetracyclines; Vancomycin; Veillonella | 2022 |